Rocket Pharmaceuticals (RCKT) Net Equity Issued and Repurchased (2015 - 2024)

Rocket Pharmaceuticals has reported Net Equity Issued and Repurchased for 10 years, with the latest figure at $118.7 million in Q4 2024.

• Quarterly Net Equity Issued and Repurchased rose 169.16% year-over-year to $118.7 million in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $182.5 million (up 959.85% YoY) and the FY2024 annual result came in at $182.5 million, up 959.85% from the prior year.
• Net Equity Issued and Repurchased grew to $118.7 million in Q4 2024 per RCKT's latest filing, from $63.8 million in the prior quarter.
• Over five years, Net Equity Issued and Repurchased peaked at $171.7 million in Q3 2023 and troughed at -$171.7 million in Q4 2023.
• A 5-year average of $25.6 million and a median of $17.2 million in 2022 frame the typical range for Net Equity Issued and Repurchased.
• The widest YoY moves for Net Equity Issued and Repurchased: up 485.94% in 2023, down 378.68% in 2023.
• Over 5 years, Net Equity Issued and Repurchased stood at -$874000.0 in 2020, then plunged by 905.95% to -$8.8 million in 2021, then surged by 800.61% to $61.6 million in 2022, then sank by 378.68% to -$171.7 million in 2023, then jumped by 169.16% to $118.7 million in 2024.
• According to Business Quant data, Net Equity Issued and Repurchased over the past three periods registered $118.7 million, $63.8 million, and -$171.7 million for Q4 2024, Q3 2024, and Q4 2023 respectively.